These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38828460)

  • 1. GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy.
    Tian C; Zhang H; Liu J; Xu M; Ma L
    Front Pharmacol; 2024; 15():1396133. PubMed ID: 38828460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer.
    Zekri J; Rasool H; Rizvi SAJ; Eldeeb H; Al-Gahmi A; Farag K; Rasmy A
    Womens Health (Lond); 2023; 19():17455057231166837. PubMed ID: 37148305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients.
    Liu H; Hu X; Wang L; Du T; Feng J; Li M; Liu L; Liu X
    Front Surg; 2022; 9():862617. PubMed ID: 35647022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.
    Cheng S; Wang J; Wang Y; Qi L; Li F; Liu J; Chen J; Fan Y; Xie L
    Eur Radiol Exp; 2023 May; 7(1):22. PubMed ID: 37183212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.
    Yang Y; Jin L; Li Y; Rao N; Gong C; Li S; Wu J; Zhao J; Ding L; Gan F; Zhang J; Feng R; Liu Z; Liu Q
    Chin J Cancer Res; 2024 Feb; 36(1):55-65. PubMed ID: 38455369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
    Swain SM; Ewer MS; Viale G; Delaloge S; Ferrero JM; Verrill M; Colomer R; Vieira C; Werner TL; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C;
    Ann Oncol; 2018 Mar; 29(3):646-653. PubMed ID: 29253081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer.
    Zhang L; Wang Y; Meng W; Zhao W; Tong Z
    Sci Rep; 2022 Aug; 12(1):14312. PubMed ID: 35995984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
    Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
    Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study.
    Wang H; Li Y; Qi Y; Zhao E; Kong X; Yang C; Yang Q; Zhang C; Liu Y; Song Z
    Front Oncol; 2022; 12():909426. PubMed ID: 35875123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.
    Xiao Y; Ding J; Ma D; Chen S; Li X; Yu K
    Front Immunol; 2022; 13():877825. PubMed ID: 35663978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Let-7f and miRNA-126 correlate with reduced cardiotoxicity risk in triple-negative breast cancer patients who underwent neoadjuvant chemotherapy.
    Zhu Z; Li X; Dong H; Ke S; Zheng WH
    Int J Clin Exp Pathol; 2018; 11(10):4987-4995. PubMed ID: 31949575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy.
    Huang P; Huang JH; Zheng YB; Cao WM; Shao XY; Chen JQ; Huang Y; Li GL; Sharma K; Zhou HH; Wang XJ; Jin HC; Chen ZH
    Front Pharmacol; 2022; 13():883600. PubMed ID: 35991878
    [No Abstract]   [Full Text] [Related]  

  • 16. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.
    Putt M; Hahn VS; Januzzi JL; Sawaya H; Sebag IA; Plana JC; Picard MH; Carver JR; Halpern EF; Kuter I; Passeri J; Cohen V; Banchs J; Martin RP; Gerszten RE; Scherrer-Crosbie M; Ky B
    Clin Chem; 2015 Sep; 61(9):1164-72. PubMed ID: 26220066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer: a retrospective study.
    Lu H; Yan H; Liao S; Deng J; Zhang J; Yao F; Zheng H; Sun S; Zhang Y
    Transl Cancer Res; 2023 Jun; 12(6):1490-1502. PubMed ID: 37434677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
    van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
    Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab.
    Andersson AE; Linderholm B; Giglio D
    Acta Oncol; 2021 Apr; 60(4):475-481. PubMed ID: 33191817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.